VCENNA utilizes data science and machine learning algorithms to map the effects of natural psychedelic extracts, developing neuro-pharmaceuticals aimed at enhancing mental wellness. The company focuses on creating targeted pharmacological solutions that promote therapeutic treatment through optimized formulations for clinical group therapy.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current mental wellness treatments may not fully address the needs of all patients, and there is a need for more targeted pharmacological solutions that can promote therapeutic treatment. Optimizing formulations for clinical group therapy presents a challenge in the field of neuro-pharmaceuticals.
Solution
VCENNA is developing neuro-pharmaceuticals using data science and machine learning algorithms to map the effects of natural psychedelic extracts. The company focuses on creating targeted pharmacological solutions that promote therapeutic treatment through optimized formulations for clinical group therapy. VCENNA's approach involves rigorous bio-tracking and patient monitoring to enable drug development. The company is also focused on formulation optimization and neuro-pharmaceuticals treatment segmentation.
Target Audience
VCENNA's primary customers are individuals seeking mental wellness treatments and clinical group therapy providers.
Features
- Applies data science and machine learning algorithms to map the effects of natural psychedelic extracts.
- Develops formulations inspired by traditions of eastern medicine, specifically Beta-carbolines.
- Pipeline includes a 5HT Stimulant MAOi Extract Formulation (SVEN1) and a 5HT Stimulant MAOi + T1 Extracts Formulation (SVEN2).
- Employs rigorous bio-tracking for patient monitoring during drug development.
- Optimizes formulations for clinical group therapy.